## Liliane Fossati-Jimack

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8979833/publications.pdf

Version: 2024-02-01

840728 888047 19 833 11 17 citations g-index h-index papers 19 19 19 1402 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	RA-MAP, molecular immunological landscapes in early rheumatoid arthritis and healthy vaccine recipients. Scientific Data, 2022, 9, 196.	5.3	4
2	Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. Nature Medicine, 2022, 28, 1256-1268.	30.7	105
3	C3 Drives Inflammatory Skin Carcinogenesis Independently of C5. Journal of Investigative Dermatology, 2021, 141, 404-414.e6.	0.7	16
4	Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet, The, 2021, 397, 305-317.	13.7	145
5	Novel Bispecific Antibody for Synovial-Specific Target Delivery of Anti-TNF Therapy in Rheumatoid Arthritis. Frontiers in Immunology, 2021, 12, 640070.	4.8	6
6	OPO136â€RITUXIMAB PREVENTS THE PROGRESSION OF B-CELL DRIVEN INFLAMMATORY INFILTRATE IN THE MINOR SALIVARY GLANDS OF PRIMARY SJOGREN'S SYNDROME BY DOWNREGULATING IMMUNOLOGICAL PATHWAYS KEY IN ECTOPIC GERMINAL CENTRE ORGANIZATION: RESULTS FROM THE TRACTISS TRIAL. Annals of the Rheumatic Diseases, 2021, 80, 79-80.	0.9	2
7	NKp30 Receptor Upregulation in Salivary Glands of Sjögren's Syndrome Characterizes Ectopic Lymphoid Structures and Is Restricted by Rituximab Treatment. Frontiers in Immunology, 2021, 12, 706737.	4.8	8
8	B Cell Synovitis and Clinical Phenotypes in Rheumatoid Arthritis: Relationship to Disease Stages and Drug Exposure. Arthritis and Rheumatology, 2020, 72, 714-725.	5 <b>.</b> 6	33
9	Unique expansion of IL-21+ Tfh and Tph cells under control of ICOS identifies Sjögren's syndrome with ectopic germinal centres and MALT lymphoma. Annals of the Rheumatic Diseases, 2020, 79, 1588-1599.	0.9	83
10	OP0217â€INVOLVEMENT OF LARGE JOINTS AT DISEASE PRESENTATION IS ASSOCIATED WITH DIVERSE HISTOPATHOLOGICAL FEATURES AND CLINICAL OUTCOMES IN EARLY RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases, 2020, 79, 134.1-135.	0.9	0
11	Extracellular traps and PAD4 released by macrophages induce citrullination and auto-antibody production in autoimmune arthritis. Journal of Autoimmunity, 2019, 105, 102297.	6.5	37
12	THU0058â€B CELL SYNOVITIS AND CLINICAL PHENOTYPES IN RHEUMATOID ARTHRITIS AT DIFFERENT DISEASE STAGES. , 2019, , .		2
13	NK cell recruitment in salivary glands provides early viral control but is dispensable for tertiary lymphoid structure formation. Journal of Leukocyte Biology, 2019, 105, 589-602.	3.3	5
14	Mast cells in early rheumatoid arthritis associate with disease severity and support B cell autoantibody production. Annals of the Rheumatic Diseases, 2018, 77, 1773-1781.	0.9	52
15	Complement receptor 3 mediates renal protection in experimental C3 glomerulopathy. Kidney International, 2016, 89, 823-832.	5.2	7
16	Triglyceride-Rich Lipoproteins Modulate the Distribution and Extravasation of Ly6C/Gr1low Monocytes. Cell Reports, 2015, 12, 1802-1815.	6.4	33
17	Mechanisms of complement activation by dextran-coated superparamagnetic iron oxide (SPIO) nanoworms in mouse versus human serum. Particle and Fibre Toxicology, 2014, 11, 64.	6.2	79
18	IL-10-producing regulatory B cells induced by IL-33 (BregIL-33) effectively attenuate mucosal inflammatory responses in the gut. Journal of Autoimmunity, 2014, 50, 107-122.	6.5	158

#	Article	IF	CITATIONS
19	Phagocytosis Is the Main CR3-Mediated Function Affected by the Lupus-Associated Variant of CD11b in Human Myeloid Cells. PLoS ONE, 2013, 8, e57082.	2.5	58